You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

Pegulicianine acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for pegulicianine acetate and what is the scope of patent protection?

Pegulicianine acetate is the generic ingredient in one branded drug marketed by Lumicell and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pegulicianine acetate has twenty-three patent family members in seven countries.

One supplier is listed for this compound.

Summary for pegulicianine acetate
International Patents:23
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:pegulicianine acetate at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pegulicianine acetate
Generic Entry Date for pegulicianine acetate*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for pegulicianine acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for pegulicianine acetate

Country Patent Number Title Estimated Expiration
Japan 7273873 ⤷  Sign Up
South Korea 20160037834 의료 이미징 장치 및 사용 방법 (MEDICAL IMAGING DEVICE AND METHODS OF USE) ⤷  Sign Up
Australia 2011336660 Methods and systems for spatially identifying abnormal cells ⤷  Sign Up
Canada 2824724 PROCEDES ET SYSTEMES DESTINES A IDENTIFIER SPATIALEMENT DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS) ⤷  Sign Up
Canada 2906056 DISPOSITIF D'IMAGERIE MEDICALE ET SES PROCEDES D'UTILISATION (MEDICAL IMAGING DEVICE AND METHODS OF USE) ⤷  Sign Up
Japan 6478971 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2014152389 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.